Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2021, 165(3):322-327 | DOI: 10.5507/bp.2020.023

The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study

Jiri Zelinkaa, Jiri Blahaka, Vojtech Perinaa, Rita Pacasovab, Jana Treglerovaa, Oliver Bulik
a Clinic of Oral and Maxillofacial Surgery, University Hospital Brno, Czech Republic
b Transfusion and Tissue Department, University Hospital Brno, Czech Republic

Objectives: Medication-related osteonecrosis of the jaw (MRONJ) is defined as exposed bone in the maxillofacial region persisting for more than eight weeks in patients who are or were treated with antiresorptive or antiangiogenic agents and had no radiation therapy to the craniofacial region or obvious metastatic disease of the jaws. It is a recognised side effect of antiresorptive or antiangiogenic medication. To date, there is no specific gold standard treatment for MRONJ cases. The aim of this study was to evaluate the successful rate of surgical treatment with adjuvant local application of platelet rich fibrin.

Methods: 40 patients treated with necrotic bone resection and adjuvant local application of platelet-rich fibrin (PRF) were included. Treatment outcomes were evaluated after 12 months.

Results: The outcome of surgical treatment was successful in 34 of all 40 patients (85%), in 12 months follow-up. If we evaluate only cases where removal of all necrotic bone was possible the success rate was increased to 94%. A significant association between size of necrotic bone and treatment response was found (P=0.014, Wilcoxon rank sum test with continuity correction).

Conclusions: Surgical treatment of MRONJ with adjuvant local PRF application proved to be very effective and safe, especially in early stages when all necrotic bone can be easily removed.

Keywords: medication related osteonecrosis of the jaw, platelet rich fibrin, surgical treatment

Received: February 2, 2020; Revised: May 2, 2020; Accepted: May 12, 2020; Prepublished online: June 26, 2020; Published: September 20, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zelinka, J., Blahak, J., Perina, V., Pacasova, R., Treglerova, J., & Bulik, O. (2021). The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study. Biomedical papers, 165(3), 322-327. doi: 10.5507/bp.2020.023
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61(9):1115-7. Go to original source... Go to PubMed...
    2. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw 2014 update. J Oral Maxillofac Surg 2014;72(10):1938-56. doi:10.1016/j.joms.2014.04.031 Go to original source... Go to PubMed...
    3. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M. Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 2010;28(4):365-83. doi:10.1007/s00774-010-0162-7 Go to original source... Go to PubMed...
    4. Lesclous P, Grabar S, Abi Najm S, Carrel JP, Lombardi T, Saffar JL, Samson J. Relevance of surgical management of patients affected by bisphosphonate-associated osteonecrosis of the jaws. A prospective clinical and radiological study. Clin Oral Invest 2014;18(2):391-9. doi:10.1007/s00784-013-0979-2 Go to original source... Go to PubMed...
    5. Montebugnoli L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, Marchetti C. Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;104(4):473-7. doi:10.1016/j.tripleo.2007.01.008 Go to original source... Go to PubMed...
    6. Nicolatou-Galitis O, Papadopoulou E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, Repousis P, Barbounis V, Migliorati CA. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112(2):195-202. doi:10.1016/j.tripleo.2011.02.037 Go to original source... Go to PubMed...
    7. Otto S, ed. Medication-Related Osteonecrosis of the Jaws: Bisphosphonates, Denosumab, and New Agents. 2015 edition. New York: Springer; 2014. Go to original source...
    8. Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S. Surgical Approach and Laser Applications in BRONJ Osteoporotic and Cancer Patients. J Osteoporos 2012;2012. doi:10.1155/2012/585434 Go to original source... Go to PubMed...
    9. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncology 2011;47(3):185-90. doi:10.1016/j.oraloncology.2011.01.002 Go to original source... Go to PubMed...
    10. Freiberger JJ. Utility of Hyperbaric Oxygen in Treatment of Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 2009;67(5,Suppl):96-106. doi:10.1016/j.joms.2008.12.003 Go to original source... Go to PubMed...
    11. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101(3):e37-44. doi:10.1016/j.tripleo.2005.07.008 Go to original source... Go to PubMed...
    12. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part II: platelet-related biologic features. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101(3):e45-50. doi:10.1016/j.tripleo.2005.07.009 Go to original source... Go to PubMed...
    13. Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J, Gogly B. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part III: leucocyte activation: a new feature for platelet concentrates? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101(3):e51-55. doi:10.1016/j.tripleo.2005.07.010 Go to original source... Go to PubMed...
    14. Choukroun J, Diss A, Simonpieri A, Girard MO, Schoeffler C, Dohan SL, Dohan AJ, Mouhyi J, Dohan DM. Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part IV: clinical effects on tissue healing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;101(3):e56-60. doi:10.1016/j.tripleo.2005.07.011 Go to original source... Go to PubMed...
    15. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Nagata T, Urade M, Shibahara T, Toyosawa S. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017;35(1):6-19. doi:10.1007/s00774-016-0810-7 Go to original source... Go to PubMed...
    16. Melea PI, Melakopoulos I, Kastritis E, Tesseromatis Ch, Margaritis V, Dimopoulos M, Terpos E. Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients. Int J Dent 2014;2014:427273. doi:10.1155/2014/427273 Go to original source... Go to PubMed...
    17. Wutzl A, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A, Watzinger F, Schicho K, Ewers R, Millesi G. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck 2008;30(9):1224-30. doi:10.1002/hed.20864 Go to original source... Go to PubMed...
    18. Carlson ER, Basile JD. The Role of Surgical Resection in the Management of Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 2009;67(5,Suppl):85-95. doi:10.1016/j.joms.2009.01.006 Go to original source... Go to PubMed...
    19. Holzinger D, Seemann R, Klug C, Ewers R, Millesi G, Baumann A, Wutzl A. Long-term success of surgery in bisphosphonate-related osteonecrosis of the jaws (BRONJs). Oral Oncology 2013;49(1):66-70. doi:10.1016/j.oraloncology.2012.07.008 Go to original source... Go to PubMed...
    20. Longo F, Guida A, Aversa C, Pavone E, Di Costanzo G, Ramaglia L, Ionna F. Platelet Rich Plasma in the Treatment of Bisphosphonate-Related Osteonecrosis of the Jaw: Personal Experience and Review of the Literature. Int J Dent 2014;2014. doi:10.1155/2014/298945 Go to original source... Go to PubMed...
    21. Bocanegra-Pérez S, Vicente-Barrero M, Knezevic M, et al. Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw. Int. J. Oral Maxillofac. Surg 2012;41:1410-15. doi:10.1016/j.ijom.2012.04.020 Go to original source... Go to PubMed...
    22. Adornato MC, Morcos I, Rozanski J. The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J. Am. Dent. Assoc 2007;138(7):971-7. doi:10.14219/jada.archive.2007.0294 Go to original source... Go to PubMed...
    23. Kim JW, Kim SJ, Kim MR. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Brit J Oral Max Surg 2014;52(9):854-9. doi:10.1016/j.bjoms.2014.07.256 Go to original source... Go to PubMed...
    24. Nørholt SE, Hartlev J. Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. Int J Oral Maxillofac Surg 2016;45(10):1256-60. doi:10.1016/j.ijom.2016.04.010 Go to original source... Go to PubMed...
    25. Fernando de Almeida Barros Mourão C, Calasans-Maia MD, Del Fabbro M, Le Drapper Vieira F, Coutinho de Mello Machado R, Capella R, Miron RJ, Gomes Alves G. The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series. J Stomatol Oral Maxillofac Surg February 2020;121(1):84-9. doi:10.1016/j.jormas.2019.02.011 Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content